CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company develops, markets, and distributes medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. The company offers XCEL SphygmoCor for measuring central arterial pressure; SphygmoCor Inside, which uses pulse waveform analysis for calculating central pressures and arterial stiffness; SphygmoCor technology for non-invasive measuring of the central arterial pressure waveform, central aortic pressures, and pulse wave velocity; and SphygmoCor system for measuring central arterial pressure waveform analysis. It also provides TeleHealth Services, which provides digital, e-commerce, and mobile tools for patients to connect online with health coaches. CardieX Limited has a strategic collaboration with Blumio Inc. to develop non-invasive wearable technologies that identify patient risk profiles for hypertension, CVD, and related disorders; and a joint development agreement with Mobvoi Information Technology Co. Ltd to develop an ecosystem of smart heart and other consumer health applications for the Google Wear OS platform. It offers its devices and services to hospitals, clinics, research institutions and pharmaceutical companies. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was incorporated in 2005 and is based in Sydney, Australia.